Marginal Zone Lymphoma

• CLINICAL_TRIALS withdrawal · 2024-04-25
  Clinical Trial Update: CpG-STAT3 siRNA CAS3/SS3 and Localized Radiation Therapy for the Treatment of Relapsed/Refractory B-Cell NHL [Phase 1]

  A Phase 1 trial investigating CpG-STAT3 siRNA CAS3/SS3 with localized radiation for relapsed/refractory B-cell non-Hodgkin lymphomas has bee…

• EMA withdrawal · 2023-02-10
  EMA Application withdrawn: Aliqopa (copanlisib dihydrochloride) — Bayer AG

  The EMA has withdrawn the application for Aliqopa (copanlisib dihydrochloride) by Bayer AG for its use in lymphoma subtypes including margin…

• CLINICAL_TRIALS withdrawal · 2022-07-18
  Clinical Trial Update: To Evaluate Efficacy and Safety of Parsaclisib Plus Either Rituximab or Obinutuzumab in R/R Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) (CITADEL-302) [Phase 3]

  A Phase 3 clinical trial evaluating parsaclisib with rituximab or obinutuzumab in relapsed/refractory follicular lymphoma and marginal zone …

• CLINICAL_TRIALS withdrawal · 2021-03-17
  Clinical Trial Update: A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA) [Phase 3]

  Phase 3 trial BRAVURA evaluating duvelisib with rituximab and bendamustine versus placebo in indolent non-Hodgkin lymphoma was withdrawn.

• CLINICAL_TRIALS withdrawal · 2017-05-19
  Clinical Trial Update: Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma [Phase 2]

  The Phase 2 trial of Brentuximab Vedotin, Bendamustine, and Rituximab for relapsed or refractory B-cell non-Hodgkin lymphoma has been withdr…

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• CLINICAL_TRIALS withdrawal · 2013-06-06
  Clinical Trial Update: Obatoclax Mesylate, Rituximab, and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma [Phase 1, Phase 2]

  A Phase 1/2 clinical trial evaluating obatoclax mesylate in combination with rituximab and bendamustine hydrochloride for relapsed or refrac…